comparemela.com

Latest Breaking News On - Thomas karalis - Page 3 : comparemela.com

Antengene Announces XPOVIO® Approved by the TGA in Australia for the Treatment of Relapsed and/or Refractory Multiple Myeloma and Triple Class-Refractory Multiple Myeloma

- XPOVIO®, in combination with bortezomib and dexamethasone (XBd), gives patients with relapsed and/or refractory multiple myeloma, a new treatment option. - XPOVIO®, in combination with dexamethasone (Xd), gives patients with triple class refractory multiple myeloma, a new treatment option. These patients have poor prognosis and limited treatment options. - XPOVIO® is the first of a new class.

Hong kongUnited statesSouth koreaAndrew spencerThomas karalisJay meiAsia pacificPeter qianCompany annualHong kong stock exchangePrnewswire antengene corporation limitedAntengene corporation limitedDrug administrationAustralian government department of healthTherapeutic goods administrationCorporation limited

Antengene Announces XPOVIO® Regulatory Approval in Singapore for the Treatment of Relapsed and/or Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Three Indications

/PRNewswire/ Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, global biopharmaceutical company dedicated to discovering,.

Hong kongSouth koreaThomas karalisJay meiAsia pacificPeter qianSelective inhibitor of nuclearKaryopharm therapeutics incCompany annualAntengene corporationHong kong stock exchangeAntengene corporation limitedDrug administrationSelective inhibitorNuclear exportKaryopharm therapeutics

Antengene Announces XPOVIO® Regulatory Approval in Singapore for the Treatment of Relapsed and/or Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Three Indications

Antengene Announces XPOVIO® Regulatory Approval in Singapore for the Treatment of Relapsed and/or Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Three Indications - read this article along with other careers information, tips and advice on BioSpace

Hong kongSouth koreaThomas karalisJay meiAsia pacificPeter qianKaryopharm therapeutics incCompany annualAntengene corporationDrug administrationSelective inhibitor of nuclearHealth sciences authorityHong kong stock exchangeCompany codesPrnewswire antengene corporation limitedAntengene corporation limited

Antengene Announces Financial Results for Full Year 2020

Antengene Announces Financial Results for Full Year 2020
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

Bo shanNew zealandHong kongSouth koreaKevin lynchJohnf chinZhinuan yuJay meiAsia pacificDirk hoenemannHead of medical affairsAdministrative committee of the binhai new areaAntengene corporationPartner companyKorean ministry of foodChina national medical products administration

Antengene Appoints Minyoung Kim as General Manager of Antengene South Korea

Antengene Appoints Minyoung Kim as General Manager of Antengene South Korea News provided by Share this article Share this article SHANGHAI and SEOUL, South Korea, March 14, 2021 /PRNewswire/ Antengene Corporation Limited ( Antengene , SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing, and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced the appointment of Ms. Minyoung Kim as General Manager of Antengene South Korea. Antengene is actively expanding geographic presence across APAC Markets and has established a wholly-owned subsidiary in Seoul. Minyoung Kim Minyoung will lead Antengene operations in South Korea and will be responsible for implementing Antengene s vision, building a talented & highly respected organization, collaborating closely with Korean healthcare professionals and commercializing Antengene s innovative portfolio of novel therapies to expand

Soult ukpyolsiSouth koreaEteläuomen läiSouth koreanThomas karalisJay meiAsia pacificEli lillyMinyoung kimSeoul national university hospitalHelsinki school of economicsAalto universitySeoul national universityAntengene corporation limitedGeneral managerIpsen korea

vimarsana © 2020. All Rights Reserved.